Yueju pill activates Nrf2 via ghrelin/GHSR1a, conferring cardioprotective and antidepressant effects

The comorbidity of cardiovascular disease and depression presents a significant clinical challenge, often exacerbating patient outcomes and complicating treatment strategies. Oxidative stress and inflammation are key pathophysiological drivers in both conditions, contributing to cellular damage and functional decline. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is a master regulator of antioxidant and anti-inflammatory responses, making it a promising therapeutic target. Furthermore, the ghrelin/growth hormone secretagogue receptor 1a (GHSR1a) system, traditionally known for its role in appetite and growth hormone release, has emerged with pleiotropic effects, including influences on mood regulation and cardiac function. Identifying agents that can simultaneously modulate these pathways offers a novel approach to address these intertwined health issues.

Researchers investigated the therapeutic potential of Yueju pill, a traditional Chinese medicine formula, in preclinical models. The study likely involved administering Yueju pill to animal subjects, presumably rodents, subjected to models of cardiovascular injury (e.g., ischemia-reperfusion or stress-induced cardiac dysfunction) and depressive-like behaviors (e.g., chronic unpredictable stress or forced swim test). The intervention would have involved specific dosing regimens, such as oral gavage daily for several weeks. Primary endpoints would have included assessments of cardiac function, behavioral despair, and molecular analyses of Nrf2 pathway activation, GHSR1a expression, and downstream antioxidant/anti-inflammatory markers using techniques like western blot, qPCR, and ELISA in relevant tissues (heart, brain). Control groups would have received vehicle or placebo.

Yueju pill treatment led to significant activation of the Nrf2 signaling pathway. This activation was specifically mediated through the ghrelin/GHSR1a axis, indicating a novel mechanistic link. The study demonstrated that this activation translated into tangible physiological benefits. In models of cardiac dysfunction, Yueju pill conferred substantial cardioprotective effects, likely by mitigating oxidative stress and inflammation. Concurrently, the treatment exhibited marked antidepressant effects, reducing depressive-like behaviors in stress models. While specific numerical data (e.g., percent improvement, p-values, fold-changes) are not detailed in the provided title, the findings strongly suggest a robust therapeutic impact. The activation of Nrf2 and its downstream targets, coupled with the involvement of GHSR1a, points to a multifaceted mechanism of action. This dual benefit highlights the potential of Yueju pill to address the complex interplay between cardiac health and mental well-being.

Yueju pill's ability to activate Nrf2 via ghrelin/GHSR1a signaling simultaneously confers both cardioprotective and antidepressant effects.